et al Perceval 10.95 0a 2 0 0 2 (5.3%) 1 major bleed 0 NR D’Onofrio (2012)() S (moderate AR (5.3%) (2.6%) (n = 38) 2+/3+) TAVI 10.25 8% 2 0 0 1 (2.6%) 1 major bleed; 1 2 NR fatal bleed (n = 38) (moderate AR (5.3%) (5.3%) 2+/3+) (5.3%) et al Perceval 11.1 19.4% 1 0 0 1 (3.2%) NR 0 NR D’Onofrio (2013)() S (all at least mild; (3.2%) (n = 31) AR ≥1+/3) TAVI 10.7 28.7% 7 4 (2.8%) 5 7 (4.9%) NR 10 NR (n = 143) (all at least mild; (4.9%) (3.5%) (7%)† AR ≥1+/3) Standard 16.5 1.8% 1 0 1 NR 1 NR 0 AVR (all at least mild; (0.9%) (0.9%) (0.9%) (n = 112) AR ≥1+/3) Gilmanov et al Sutureless 11 NR 6 (4.5%) 2 (1.5%) 2 (1.5%) 1 (0.8%) 7% requiring 1 (0.8%) Median (2014)() (n = 133) reexploration 10mo:d 4% Standard 12 NR 3 (2%) 0 0 0 4% requiring 2 (1.5%) 5% AVR reexploration (n = 133) Pollari et al Perceval NR NR 5 (6%) 3 (4%) NR NR 2% requiring 2 (2.4%) Median (2014)() S (including reexploration 13mo:d TIA) Mean blood tx (n = 82) 2.5% 1.2U*
D’Onofrio et al (2012)() Perceval S (n = 38) 10.95 0a (moderate AR 2+/3+) 2 (5.3%) 0 0 2 (5.3%) 1 major bleed (2.6%) 0 NR TAVI (n = 38) 10.25 8% (moderate AR 2+/3+) 2 (5.3%) 0 0 1 (2.6%) 1 major bleed; 1 fatal bleed (5.3%) 2 (5.3%) NR D’Onofrio et al (2013)() Perceval S (n = 31) 11.1 19.4% (all at least mild; AR ≥1+/3) 1 (3.2%) 0 0 1 (3.2%) NR 0 NR TAVI (n = 143) 10.7 28.7% (all at least mild; AR ≥1+/3) 7 (4.9%) 4 (2.8%) 5 (3.5%) 7 (4.9%) NR 10 (7%)† NR Standard AVR (n = 112) 16.5 1.8% (all at least mild; AR ≥1+/3) 1 (0.9%) 0 1 (0.9%) 0 NR 1 (0.9%) NR Gilmanov et al (2014)() Sutureless (n = 133) 11 NR 6 (4.5%) 2 (1.5%) 2 (1.5%) 1 (0.8%) 7% requiring reexploration 1 (0.8%) Median 10mo:d 4% Standard AVR (n = 133) 12 NR 3 (2%) 0 0 0 4% requiring reexploration 2 (1.5%) 5% Pollari et al (2014)() Perceval S (n = 82) NR NR 5 (6%) 3 (4%) (including TIA) NR NR 2% requiring reexploration Mean blood tx 1.2U* 2 (2.4%) Median 13mo:d 2.5%
sutureless-aortic-valve-replacement-tier3-assessment.docx